Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

August 28, 2015 11:50 PM ET


Company Overview of Aridis Pharmaceuticals Inc.

Company Overview

Aridis Pharmaceuticals Inc., a biopharmaceutical company, develops anti-infective product candidates. The company offers AR-301, an anti-Staphylococcus aureus human monoclonal antibody to treat acute pneumonia; AR-101 and AR-104 that are specific lgM monoclonal antibodies, which target pseudomonas aeruginosa; and Aerucin, a broadly reactive monoclonal antibody against Pseudomonas aeruginosa. It also provides Panaecin, a small molecule anti-infective gallium compound with broad spectrum activities against bacteria, viruses, and fungi; AR201, a human monoclonal antibody, which treats respiratory syncytial virus infections; and AR401, a human monoclonal antibody for the treatment of Nosocomial ...

5941 Optical Court

San Jose, CA 95138

United States

Founded in 2003





Key Executives for Aridis Pharmaceuticals Inc.

Co-Founder, Chief Executive Officer and Director
Co-Founder, Chairman and President
Chief Financial Officer and Director
Age: 64
Head of Finance
Chief Medical Officer
Compensation as of Fiscal Year 2015.

Aridis Pharmaceuticals Inc. Key Developments

Aridis Pharmaceuticals Inc. Appoints Fred Kurland as Chief Financial Officer

Aridis Pharmaceuticals Inc. announced the appointment of Fred Kurland, a seasoned pharmaceutical executive, as the company's first Chief Financial Officer. Prior to joining the company, Fred Kurland served as Chief Financial Officer, Vice President of Finance and Secretary of XOMA Corporation since December 2008. He was responsible for directing the company's financial strategies and financing activities.

Aridis Pharmaceuticals Expands Phase 2a Trial into the U.S. for Monoclonal Antibody AR-301 for the Treatment of Acute Pneumonia

Aridis Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for AR-301, also referred to as Salvecin™, the company's fully human anti-Staphylococcal a-toxin IgG1 monoclonal antibody being developed for the treatment of hospital-acquired and ventilator-associated pneumonia (HAP and VAP) caused by Staphylococcus aureus, including multi-drug resistant 'MRSA' strains. Acceptance of the IND application enables Aridis to expand and accelerate its current Phase 2a study of AR-301 as an adjunctive therapy with standard-of-care antibiotics into the United States. The study is currently underway in three European countries, with further expansion into the United Kingdom also planned. Top-line results from the accelerated Phase 2a study are expected in the first half of 2016. The European Phase 2a clinical trial is a randomized, double-blind, placebo-controlled, single ascending dose study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of a single intravenous administration of AR-301 in patients with severe pneumonia caused by S. aureus. Depending on the outcome of Phase 2a clinical trial, Aridis expects the subsequent phase of clinical testing of AR-301 to be either a Phase 2b trial, followed by a Phase 3 trial in pneumonia patients. AR-301 was discovered by screening B-cell lymphocytes of a patient with confirmed S. aureus infection and developed using Aridis' proprietary MAbIgX® technology. It binds and neutralizes S. aureus alpha toxin, preventing alpha toxin-mediated destruction of human cells. There is no anti-infective on the market that specifically neutralizes the pathogenic affects brought about by S. aureus toxins and Aridis believes that this mechanism of action complements the bacterial killing properties of many conventional antibiotics, as the bacterial toxins left behind following antibiotic-mediated killing can still be neutralized by AR-301.

Aridis Pharmaceuticals Inc. Appoints Craig Gibbs to Board of Directors

Aridis Pharmaceuticals Inc. announced the appointment of former Gilead Sciences executive Craig Gibbs, Ph.D., MBA, to its Board of Directors. Dr. Gibbs currently serves on the Board of Directors of Tobira Therapeutics and is an advisor to several biotechnology companies and venture capital firms.

Similar Private Companies By Industry

Company Name Region
PHLO Corp. United States
Nimbus Therapeutics, Inc. United States
AndroScience Corporation United States
Melanx Corporation United States
PharmaSphere, LLC United States

Recent Private Companies Transactions

Private Placement
September 18, 2014

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Aridis Pharmaceuticals Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at